Swarm Oncology

Swarm Oncology is a pre-clinical biotechnology company developing personalised T cell therapies for advanced solid cancers.

Its platform combines in vivo immune priming with proprietary ex vivo cell processing to generate large numbers of potent, non-exhausted T cells with tumour-homing phenotypes, addressing a key limitation of current immunotherapy approaches.

The platform has demonstrated consistent T cell production from patient samples, including immunocompromised patients, and the company expects to advance its first candidate into clinical trials.